Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome

Gut

Volumn 57, Issue 10, 2008, Pages 1469-1478

  Valla, D C ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; BUSULFAN; CONTRACEPTIVE AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; GEMTUZUMAB OZOGAMICIN; HEPARIN; MELPHALAN; MERCAPTOPURINE; OXALIPLATIN; TIOGUANINE; URETHAN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BEHCET DISEASE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BUDD CHIARI SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LIVER DISEASE; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PORTOSYSTEMIC ANASTOMOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SINUSOIDAL OBSTRUCTION SYNDROME; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VEIN OCCLUSION;

ANTICOAGULANTS; BUDD-CHIARI SYNDROME; HEPATIC VEINS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER; RISK FACTORS;

EID: 52649106473     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.133637     Document Type: Review

References (72)

1. Garcia-Tsao G. Congenital vascular malformation. In: Rodès J, Benhamou JP, Blei AT, Reichen J, Rizzetto M, eds. Textbook of hepatology. Oxford, UK: Blackwell Publishing Ltd, 2007:1418-24.
2. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42.
3. Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
4. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002;22:15-26.
5. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003;38:793-803.
6. De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-8.
7. Wanless IR, Peterson P, Das A, et al. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990;12:1166-74.
8. Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996;11:170-9.
9. Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994,73:21-36.
10. Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994;106:1042-7.
11. Mahmoud AE, Mendoza A, Meshikhes AN, et al. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM 1996;89:37-43.
12. Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of venocentric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. Hepatology 1998;27:488-96.
13. Kew NIC, McKnight A, Hodkinson J, et al. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks. Hepatology 1989;9:121-5.
14. Miller WJ, Federie MP, Straub WH, et al. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging 1993;18:329-35.
15. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
16. Tavill AS, Wood EJ, Kreel L, et al. The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 1975;68:509-18.
17. Mahmoud AEA, Helmy AS, Billingham S, et al. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997;9:485-9.
18. Zsitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:84-9.
19. Tang TJ, Batts KP, de Groen PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol 2001;35:338-43.
20. Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-8.
21. Ringe B, Lang H, Oldhafer KJ, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995;21:1337-44.
22. Campbell DA, Rolles K, Jamieson N, et al. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988;166:511-8.
23. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-91.
24. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-8.
25. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44:1528-34.
26. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
27. Hussein K, Bock O, Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathobiology 2007;74:72-80.
28. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14.
29. Kiladjian JJ, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008;111:4922-9.
30. Regina S, Herault 0, D'Alteroche L, et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-61.
31. Colaizzo D, Amitrano L, lannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet 2007;44:412-6.
32. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-8.
33. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005;129:553-60.
34. Mercier E, Lissalde-Lavigne G, Gris JC. JAK2 V617F mutation in unexplained loss of first pregnancy. N Engl J Med 2007;357:1984-5.
35. Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48:264-268.
36. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14.
37. Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004;19:S204-11.
38. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005:1-12.
39. Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003;37:510-9.
40. Murad SD, Valla DC, de Groen PC, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006;101:83-90.
41. Paradis V, Bieche I, Dargere D, et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut 2005;54:1776-81.
42. Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008;57:828-35.
43. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
44. Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006;44:1308-16.
45. Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006;55:878-84.
46. Hernandez-Guerra M, Turnes J, Rubinstein P, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004;40:1197-202.
47. Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132-9.
48. Rafta S, Heydtmann M, Plessier A, et al. Treatment of Budd-Chiari syndrome with TIPS. Long-term results in 124 patients and evaluation of prognostic factors. J Hepatol 2007;46:S36-7.
49. Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol 2006;44:520-8.
50. Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl 2007;13:1285-94.
51. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. A prospective follow-up study on 163 patients with Budd-Chiari syndrome: results from the european network for vascular disorders of the Liver (EN-Vie). J Hepatol 2007;46:S4.
52. Sempoux C, Horsmans Y, Geubel A, et al. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 1997;26:128-34.
53. DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis 2007;27:390-400.
54. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999;29:1779-91.
55. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004;104:1574-7.
56. Kaufmann P, Haschke M, Torok M, et al. Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. Ther Drug Monit 2006;28:766-74.
57. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35:17-23.
58. Abutalib SA, Tallman MS. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol 2006;7:343-69.
59. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6.
60. Ramasamy K, Lim ZY, Pagliuca A, et al. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006;38:823-4.
61. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003;102:820-6.
62. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008;41:229-37.
63. Imran H, Tleyjeh IM, Zirakzadeh A, et al. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006;37:677-86.
64. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-83.
65. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:137-43.
66. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of preemptive antithrombin III replacement and combined antithrombin lll/defibrotide therapy. Haematologica 2006;91:795-800.
67. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-6.
68. Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000;25:987-92.
69. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111:1122-9.
70. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603-8.
71. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61.
72. Langlet P, Escolano S, Valla D, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003;39:496-501.